Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries.
Although many studies have dealt with adverse effects (AEs) and quality of life (QoL) in prostate cancer (PCa) patients, the quantification of the patients' perspective on AE-related reduction in QoL has been less studied. This study describes the impact of self-reported local (erectile, bowel, urinary dysfunction) or systemic (mental distress, fatigue, virility loss) AEs on QoL reduction. Nordic PCa patients completed a questionnaire containing 84 multiple-choice questions. The main outcome variable of the survey was patient-reported PCa-induced QoL reduction, assessed by descriptive and regression analyses. The level of significance was p < 0.05. Among 6200 patients, 39% described their QoL as reduced owing to the PCa trajectory: radical prostatectomy group (RPGroup): 42%, radiotherapy without hormones (RADGroup): 27%, hormones (HormGroup): 47% and no treatment (NoTrtGroup): 19%. Except for the NoTrtGroup, urinary leakage and fatigue doubled the risk of QoL reduction, while virility loss and erectile dysfunction tripled the risk. Significant intergroup differences emerged for the age-adjusted odds of QoL reduction: RPGroup (0.66), RADGroup (0.40), HormGroup (0.95) and NoTrtGroup (0.22). After RP, RAD or hormone treatment of PCa, systemic AEs, in particular loss of virility, significantly reduce PCa patients' QoL similarly to or more than local AEs. The probability of reduced QoL is highest during hormone treatment and lowest in patients without anticancer therapy, and seems lower in patients treated with RAD without hormones than after RP. The treatment-related risk of reduced QoL due to systemic AEs should become a part of the pretreatment counselling of patients.